AABB is the voice of the blood and cellular therapies community before the Food and Drug Administration and FDA advisory committees, such as the Blood Products Advisory Committee and Cellular, Tissue, and Gene Therapies Advisory Committee. The Association engages stakeholders within AABB's membership and the broader community to develop materials that provide FDA with the community’s position on draft guidances, proposed regulations and policies, and research priorities. These AABB-led efforts create an important dialogue with federal regulators that helps promote a strong and safe supply of blood and cells.
REGULATORY UPDATE: FDA Draft Guidance Proposes Selective Donor Testing Strategy for Malaria Risk
January 15, 2025
OneBlood Becomes First Blood Center to Provide FDA-Licensed High-Titer COVID-19 Convalescent Plasma
January 15, 2025
REGULATORY UPDATE: AABB Releases Laboratory-Developed Tests - Stage 1 Toolkit
January 15, 2025